Text size :

Healthcare, Ronzulli: “Accessible innovation reduces hospitalizations and indirect costs”

ADNKRONOS

November 11, 2026

Rome, Nov 10. (Adnkronos Health) – “Making innovation accessible is not just a clinical response but also an investment to reduce hospitalizations and indirect costs.” So said Licia Ronzulli, Vice President of the Senate, in the message sent on the occasion of the meeting ‘Respiratory Health in Italy and Therapeutic Innovation’, promoted today in Rome by Healthcare Policy, in the Senate Library, with the unconditional contribution of GlaxoSmithKline. “Chronic respiratory diseases such as severe asthma, COPD and chronic rhinosinusitis with nasal polyposis, for which biological therapies exist today, represent a growing challenge for our healthcare system – she emphasizes – They are often underdiagnosed, profoundly affect the quality of life and generate high costs in terms of hospitalizations, exacerbations and loss of productivity.”

Regarding chronic respiratory diseases, the Vice President of the Senate recalls, “the National Chronic Disease Plan has been updated. In 2024, the guideline document for the prevention and integrated management of severe asthma was adopted, with a State-Regions Agreement. Innovative biological therapies for severe asthma, COPD and nasal polyposis have been made available and reimbursed by the National Health Service.” Furthermore, “a permanent working group aimed at a National Strategic Plan on respiratory health” has been launched.

“Prevention must become the central element of healthcare in the coming years – Ronzulli points out – We cannot limit ourselves to treating when the disease is already advanced.” Early diagnosis and telemedicine can help intercept signs of worsening, improve the follow-up of chronic patients and reduce unnecessary access to emergency rooms and hospitals. “A preventive approach reduces exacerbations, improves quality of life and, over time, also lightens costs for the system,” she concludes.

Jiji Press

Related

Page TOP